• 2010

Company Description

Antibe Therapeutics develops novel anti-inflammatory drugs that are improved versions of existing drugs.

Antibe designs and develops new pharmaceuticals. We focus on diseases characterized by inflammation, pain and/or vascular dysfunction. Our drug design approach is to create new drugs by improving existing, proven drugs. Our technology platform enables us to chemically link an existing drug to a hydrogen sulfide-releasing moeity. Hydrogen sulfide (H2S) is one of several so- called gaseous mediators. Gaseous mediators are naturally occurring substances found in the human body. Acting as neuromodulators, immunomodulators and vasodilators, gaseous mediators such as H2S regulate fundamental cellular processes. Antibe believes that H2S has tremendous therapeutic potential. Antibe’s R&D is guided by a leading team of pharmaceutical researchers and advisors. The team includes a Nobel Prize winner, high successful entrepreneurs and senior scientists affiliated with major research institutions worldwide.